Cuban Academy of Sciences develops vaccines for the treatment of non-small cell lung cancer- Vaxira and CIMAvax. This latest type of vaccine that can treat non-small cell lung cancer (NSCLC) has undergone phase 3 clinical validation and has a good effect on non-small cell lung cancer. It has now entered clinical applications in Kuba i Peru. Rezultati ovog uzbudljivog istraživanja omogućili su bivšem američkom predsjedniku Barack Obama ukinuti 55-godišnju zabranu trgovine nakon posjeta Kuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
Što je CIMAvax?
CIMAvax-EGF is a rak pluća treatment that was developed in Cuba. It is a type of imunoterapija that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced karcinom pluća nedrobnih stanica (NSCLC).
Kako djeluje CIMAvax?
Developed by researchers at the Center for Molecular Immunology (CIM) in Havana, Cuba, CIMAvax-EGF blocks a type of protein — epidermal growth factor (EGF) — that cancer cells need to grow. It does not kill cells directly, cancerous cells or otherwise, but “starves” them by preventing EGF from attaching to its proper receptor (EGFR) on the cell. This connection is required for the cell to grow and proliferate. Without it, the cancer cell does not multiply, and dies. CIMAvax blocks EGF by manipulating the patient’s immune response.
"Protein-nosač" u CIMAvaxu pokreće imunološki sustav da stvara antitijela protiv EGF proteina kako bi ga neutralizirao. To iscrpljuje cirkulirajući EGF iz krvi, oduzimajući stanicama raka ovaj važan ključ rasta i preživljavanja.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged tumor stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Što je Vaxira?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Racotumomab je anti-idiotipsko monoklonsko antitijelo koje u pacijenata inducira snažan imunološki odgovor na specifične glikolirane gangliozide (NeuGcGM3) prisutne u stanicama tumora. Vaxira® povećava preživljenje bolesnika s NSCLC u rekurentnim ili uznapredovalim stadijima (IIIB / IV) u usporedbi s najboljom potpornom njegom. Vaxira® se dobro podnosi i njegov sigurnosni profil je prihvatljiv. Najčešće nuspojave su lokalizirane (na mjestu primjene), blage i prolazne.
Čak su i oni pacijenti koji su imunizirani Vaxirom® nakon što je bolest napredovala, pokazali poboljšanje ukupnog preživljenja.
formulacija: Svaka bočica VAXIRA® sadrži: mAb Racotumomab 1.00 mg, aluminijev hidroksid [Al (OH) 3] 5.00 mg, tris (hidroksimetil) aminometan 12.14 mg, natrijev klorid 3.40 mg, voda za injekcije qs 1.0 ml. Vaxira® je imunoterapijsko sredstvo koje se sastoji od anti-idiotipskog monoklonskog antitijela Racotumomab i aluminijevog hidroksida (AH), široko korištenog pomoćnog sredstva. AH pojačava proizvodnju antitijela, ali nije ni imunogen ni hapten. Ponaša se kao depo na mjestu ubrizgavanja iz kojeg se antigen polako oslobađa i istodobno potiče stvaranje granuloma koji privlače imunokompetentne stanice poput plazme koje proizvode antitijela. AH može izravno stimulirati monocite da proizvode proupalne citokine koji mogu aktivirati T stanice, a također može stimulirati odgovor B stanica.
Kako kupiti CIMAvax i Vaxira u Indiji?
CIMAvax and Vaxira at present are not available in Indija. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
